Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cue Biopharma (CUE) EPS (Basic) (2018 - 2025)

Historic EPS (Basic) for Cue Biopharma (CUE) over the last 8 years, with Q3 2025 value amounting to -$0.07.

  • Cue Biopharma's EPS (Basic) rose 5882.35% to -$0.07 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.43, marking a year-over-year increase of 5274.73%. This contributed to the annual value of -$0.71 for FY2024, which is 3622.02% up from last year.
  • Per Cue Biopharma's latest filing, its EPS (Basic) stood at -$0.07 for Q3 2025, which was up 5882.35% from -$0.09 recorded in Q2 2025.
  • Cue Biopharma's 5-year EPS (Basic) high stood at -$0.07 for Q3 2025, and its period low was -$0.44 during Q1 2022.
  • For the 5-year period, Cue Biopharma's EPS (Basic) averaged around -$0.27, with its median value being -$0.29 (2023).
  • Per our database at Business Quant, Cue Biopharma's EPS (Basic) tumbled by 5971.22% in 2022 and then surged by 5882.35% in 2025.
  • Quarter analysis of 5 years shows Cue Biopharma's EPS (Basic) stood at -$0.25 in 2021, then plummeted by 59.71% to -$0.4 in 2022, then rose by 27.37% to -$0.29 in 2023, then skyrocketed by 42.8% to -$0.17 in 2024, then surged by 57.8% to -$0.07 in 2025.
  • Its EPS (Basic) was -$0.07 in Q3 2025, compared to -$0.09 in Q2 2025 and -$0.17 in Q1 2025.